background
nucleic
acid
amplif
test
naat
pcr
prefer
respiratori
viru
test
due
superior
diagnost
accuraci
faster
turnaround
time
panther
respiratori
assay
fusion
includ
fluabrsv
ffabr
paraflu
advhmpvrv
offer
modular
approach
syndrom
test
fulli
autom
platform
improv
gene
target
expand
test
menu
object
studi
design
evalu
fusion
use
consecut
nasopharyng
specimen
previous
use
analysi
five
pcr
well
archiv
specimen
result
combin
specimen
posit
influenza
flua
flub
rsv
parainfluenza
piv
adenoviru
adv
humanmetapneumoviru
hmpv
rhinoviru
rv
fusion
posit
sampl
fusion
correl
histor
result
one
despit
multipl
freezethaw
cycl
collect
fusion
posit
addit
sampl
includ
flua
rsv
adv
hmpv
rv
sampl
retest
correspond
prodess
pro
assay
use
quadrupl
sampl
volum
resolv
test
confirm
fusion
result
addit
flua
rsv
adv
sensit
specif
rang
fusion
limit
detect
lod
analys
perform
varieti
flu
isol
lod
rang
log
copiesml
demonstr
superior
lod
compar
previous
publish
data
assay
concurr
analys
two
new
commerci
test
respiratori
tract
infect
rti
common
associ
signific
health
burden
major
viral
agent
rti
includ
fluab
rsv
hmpv
adv
rv
spectrum
diseas
associ
viral
infect
upper
lower
respiratori
tract
includ
common
cold
otiti
media
influenzalik
ill
croup
bronchiol
pneumonia
caus
one
virus
lead
diagnost
limit
base
symptom
alon
rapid
identif
import
therapeut
infect
control
purpos
tradit
rapid
diagnost
immunoassay
produc
quick
result
simpl
perform
suboptim
sensit
review
naat
rapid
enhanc
sensit
consid
method
choic
mani
recommend
idsa
guidelin
howev
perform
differ
observ
among
commerci
naat
particularli
sequenc
diverg
matrix
gene
virus
emerg
especi
problemat
mutat
first
observ
among
clade
commerci
assay
significantli
reduc
sensit
mutat
emerg
includ
prodess
proflu
pflu
flu
xpt
panther
respiratori
viru
assay
fullyautom
panther
system
includ
flu
abrsv
paraflu
advhmpvrv
tabl
new
system
holog
redesign
amplif
reaction
compar
pro
flua
compon
still
target
matrix
gene
use
dual
target
approach
multipl
probe
ad
redund
help
safeguard
genet
drift
flub
rsv
target
matrix
gene
adv
hexon
gene
target
design
detect
adv
genotyp
gene
target
hmpv
piv
nucleocapsid
gene
piv
rv
hemagglutininneuraminidas
region
utr
respect
test
system
also
expand
menu
viru
detect
inclus
rv
studi
look
perform
panther
respiratori
viru
panel
collect
sampl
previous
analyz
five
respiratori
viru
assay
effect
enabl
compar
analysi
popul
set
also
highli
repres
clade
truli
challeng
flua
assay
clinic
specimen
includ
consecut
nasopharyng
swab
specimen
ml
viral
transport
medium
receiv
laboratori
detect
respiratori
virus
period
winter
age
rang
yr
median
yr
pediatr
case
tabl
specimen
previous
use
prospect
analysi
pflu
pfast
holog
san
diego
ca
filmarray
respiratori
panel
rp
biofir
salt
lake
citi
ut
influenza
ab
test
ciab
roch
diagnost
indianapoli
specif
detect
flua
subsequ
xpt
cepheid
carlsbad
ca
analyz
retrospect
specimen
store
origin
test
pflupfast
rp
thaw
ciab
rp
pfast
test
frozen
thaw
frozen
xpt
test
frozen
thaw
addit
time
previou
discrep
analysi
thaw
test
fusion
select
archiv
sampl
posit
respiratori
virus
previous
test
variou
combin
naat
analyz
clinic
specimen
contain
low
ct
valu
fusion
presum
high
titer
rsv
hmpv
adv
rv
serial
dilut
endpoint
comparison
fusion
appropri
pro
assay
pflu
pfast
proparaflu
proadeno
prohmpv
holog
except
rv
sampl
compar
fusion
assay
holog
perform
fulli
autom
panther
continu
random
access
instrument
util
univers
nucleic
acid
extract
pcr
chemistri
assay
specif
reagent
avail
readi
use
reagent
cartridg
initi
specimen
ad
panther
fusion
specimen
lysi
tube
contain
buffer
mixtur
use
extract
nucleic
acid
subsequ
elut
amplifi
effect
sampl
volum
test
lod
studi
expand
newer
test
kit
cepheid
xpress
flu
xpress
market
improv
sensit
among
current
circul
strain
influenza
test
perform
accord
manufactur
packag
insert
specimen
consid
true
posit
tp
use
composit
refer
standard
cr
defin
posit
previous
publish
result
sampl
equivoc
flua
rp
consid
posit
test
method
resolv
test
involv
modif
pro
assay
enhanc
analyt
sensit
specif
viral
rna
extract
ml
specimen
twice
normal
volum
use
easymag
extractor
durham
nc
elut
volum
rna
extract
effect
sampl
volum
test
amplifi
appropri
pro
assay
smartcycl
cepheid
sensit
specif
confid
interv
ci
determin
use
microsoft
excel
redmond
wa
probit
analys
limit
detect
probabl
detect
perform
use
spss
version
ibm
armonk
ny
perform
fusion
first
evalu
use
consecut
nasopharyng
specimen
collect
peak
influenza
season
januaryfebruari
sampl
set
previous
use
prospect
analysi
ciab
pflupfast
rp
xpt
incid
flua
popul
previous
consid
exclus
true
posit
case
even
though
collect
specimen
use
multipl
studi
gone
multipl
freezethaw
cycl
ffabr
flua
posit
tp
case
tabl
one
fals
neg
sampl
previous
posit
rp
ffabr
posit
addit
sampl
previous
neg
method
addit
posit
sampl
analyz
resolv
test
involv
analyz
quadrupl
initi
specimen
volum
test
pfast
result
addit
p
specimen
result
reclassif
resolv
test
incid
flua
sampl
set
sensit
specif
ffabr
detect
circul
sampl
set
also
posit
multipl
virus
includ
rsv
adv
hmpv
hmpv
rvev
well
sampl
neg
fusion
detect
virus
posit
either
coronavirus
atyp
bacteria
tabl
fusion
correl
histor
posit
result
except
sampl
neg
fusion
rv
posit
evrv
rp
six
sampl
test
lab
develop
assay
ev
posit
exclud
fals
neg
case
fusion
posit
test
result
detect
anoth
method
includ
flua
rsv
adv
hmpv
rv
sampl
except
posit
rv
analyz
appropri
resolv
test
confirm
fusion
result
rsv
adv
sensit
fusion
rang
variou
virus
specif
rang
tabl
previou
studi
demonstr
flua
assay
perform
variat
strain
associ
perform
lod
analys
six
isol
flu
also
includ
xpress
analysi
assay
new
market
consid
improv
viral
strain
coverag
fusion
demonstr
excel
analyt
sensit
low
lod
rang
log
copiesml
tabl
lod
highli
consist
across
strain
clade
flua
assay
highli
reproduc
coeffici
varianc
rang
across
dilut
data
shown
xpress
demonstr
improv
analyt
sensit
consist
compar
manufactur
previou
test
system
howev
lod
still
rel
higher
particularli
newli
circul
subclad
assess
differ
analyt
sensit
fusion
target
versu
pro
rp
clinic
specimen
contain
rsv
hmpv
adv
rv
serial
dilut
endpoint
comparison
fusion
posit
addit
dilut
rsv
adv
two
dilut
hmpv
endpoint
posit
similar
fusion
pro
rp
rv
data
shown
sinc
introduct
numer
studi
regard
perform
naat
respiratori
viru
detect
whether
multianalyt
panel
flu
flursv
specif
variou
system
came
market
fill
individu
nich
need
review
prodess
assay
alway
thought
necessari
compar
system
gold
standard
flua
target
failur
becam
common
subclad
emerg
fact
sinc
circul
virus
gene
mutat
significantli
affect
sensit
pflu
xpt
result
mani
manufactur
modifi
system
enabl
expand
clade
coverag
inde
holog
use
influenza
redund
design
panther
fusion
fluabrsv
assay
sampl
popul
offer
uniqu
opportun
challeng
perform
fusion
sampl
contain
highli
problemat
mutat
target
region
well
evalu
perform
among
histor
clade
strain
viru
furthermor
mani
sampl
use
previou
analys
system
effect
enabl
multisystem
analysi
recent
studi
banerje
et
al
ffabr
compar
fluab
pcr
includ
ciab
rp
howev
studi
involv
select
pediatr
specimen
collect
five
respiratori
viru
season
oppos
specimen
receiv
within
period
high
incid
better
challeng
test
sensit
addit
pediatr
case
known
higher
viral
titer
also
pose
less
challeng
regard
test
sensit
result
sensit
assay
contriv
popul
compar
interestingli
studi
fusion
posit
one
viru
previous
detect
sampl
even
though
collect
use
multipl
studi
gone
multipl
freezethaw
cycl
addit
fusion
posit
sampl
confirm
true
posit
analysi
pro
use
higher
sampl
input
volum
inde
need
sensit
method
discrep
analysi
fusion
demonstr
other
leav
sampl
confirm
differ
method
clear
phenomenon
due
greater
analyt
sensit
fusion
due
true
fals
viral
detect
superior
analyt
sensit
demonstr
lod
endpoint
dilut
studi
addit
fact
test
perform
except
well
highli
compromis
sampl
term
specimen
handl
maintain
viral
rna
titer
inde
appear
fp
sampl
much
lower
viru
titer
demonstr
ct
valu
supplement
figur
henc
system
superior
analyt
sensit
would
demonstr
better
perform
specimen
furthermor
addit
posit
virus
observ
sampl
collect
period
high
viral
preval
exampl
period
flua
incid
fals
posit
detect
signal
would
random
event
equal
evid
period
low
viral
incid
also
import
point
f
p
sampl
due
rv
unfortun
one
system
avail
lab
test
rv
henc
true
refere
differ
two
system
although
manuscript
reanalysi
ciab
pro
rp
xpt
reclassif
sampl
tp
would
result
chang
sensit
specif
test
system
particular
consecut
sampl
specif
assay
would
improv
previou
public
howev
sensit
would
decreas
also
import
point
choic
refer
method
absenc
gold
standard
signific
impact
test
perform
studi
involv
submiss
diagnost
test
food
drug
administr
fda
major
criteria
would
requir
nonrefer
standard
resolv
test
would
allow
determin
posit
neg
agreement
prevent
introduct
bia
favor
new
test
howev
also
known
approach
bias
new
test
superior
analyt
sensit
situat
cr
recommend
anoth
limit
studi
fact
resolv
method
test
anoth
target
howev
need
resolv
close
match
lod
fusion
assay
low
lod
easi
feat
henc
easili
accomplish
anoth
gene
target
sake
less
bias
resolv
pro
chosen
resolv
lod
lower
commerci
assay
modifi
increas
effect
test
volum
likewis
sanger
sequenc
often
use
resolv
nt
low
lod
exampl
hiv
genotyp
perform
patient
viral
load
copiesml
inde
lab
abl
sequenc
influenza
matrix
gene
sampl
low
ct
valu
besid
exquisit
sensit
seen
fusion
system
numer
benefit
tabl
fulli
autom
high
throughput
system
ondemand
test
capabl
strategi
use
holog
modular
approach
syndrom
test
respiratori
assay
target
howev
lack
subtyp
flua
strain
anoth
plu
reagent
stabl
onboard
day
howev
refriger
need
assay
cartridg
storag
summari
fusion
offer
exquisit
sensit
detect
respiratori
virus
fulli
autom
platform
mani
option
respiratori
viru
test
nich
fusion
appear
leader
regard
sensit
protect
genom
drift
maintain
high
throughput
minim
hand
time
reagent
provid
holog
inc
usa
previous
publish
studi
use
comparison
sponsor
part
roch
diagnost
usa
studi
perform
accord
irb
requir
albani
medic
center
author
institut
receiv
sever
research
grant
abbott
molecular
bd
biomerieux
cepheid
holog
roch
diagnost
dr
stellrecht
receiv
reimburs
travel
expens
attend
meet
confer
abbott
molecular
holog
quidel
roch
diagnost
lack
subtyp
influenza
strain
modular
approach
syndrom
test
extract
use
respiratori
assay
storag
capac
reaction
tube
meet
need
maximum
specimen
capac
highli
autom
littl
hand
time
control
test
prior
specimen
test
least
one
specimen
blank
must
test
concurr
demand
test
process
respiratori
test
hr
multipl
pcr
tma
board
run
differ
protocol
one
time
reagent
stabl
onboard
day
reagent
consum
track
advanc
warn
need
need
